A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin‐producing beta‐cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin...
Alternative Titles
Full title
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_08d955a3d7174494a0f64eaccfc0dd49
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_08d955a3d7174494a0f64eaccfc0dd49
Other Identifiers
ISSN
2163-8306
E-ISSN
2163-8306
DOI
10.1002/psp4.12956
